<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients on a telemetry unit experienced an increase in <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo> in 2004 </plain></SENT>
<SENT sid="1" pm="."><plain>The purpose of this research was to determine if peripheral IV <z:chebi fb="0" ids="2663">amiodarone</z:chebi> and <z:chebi fb="0" ids="28001">vancomycin</z:chebi> influenced the incidence of <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo> in an adult cardiothoracic population </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> <z:mp ids='MP_0010140'>phlebitis</z:mp> rates range up to 27% </plain></SENT>
<SENT sid="3" pm="."><plain>In December 2004, Pharmacy diluted the <z:chebi fb="0" ids="2663">amiodarone</z:chebi> concentration to 600 mg/500 ml </plain></SENT>
<SENT sid="4" pm="."><plain>By 2005, data demonstrated a consistent decrease in the incidence of <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>However, related to institutional policies and patient safety concerns, the <z:chebi fb="0" ids="2663">amiodarone</z:chebi> infusion concentration was reversed back to 900 mg/500 ml in October 2005 </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0004418'>Thrombophlebitis</z:hpo> increased after the return to a more concentrated <z:chebi fb="0" ids="2663">amiodarone</z:chebi> IV solution </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="28001">Vancomycin</z:chebi> infusion administration did not change during this time period </plain></SENT>
<SENT sid="8" pm="."><plain>A retrospective chart review and observational, before and after study, demonstrated a correlation between <z:chebi fb="0" ids="2663">amiodarone</z:chebi> concentration and the incidence of <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="28001">Vancomycin</z:chebi> infusions appeared to prevent peripheral <z:hpo ids='HP_0004418'>thrombophlebitis</z:hpo> in the study population </plain></SENT>
<SENT sid="10" pm="."><plain>Data was compelling and resulted in the institution standardizing the more dilute <z:chebi fb="0" ids="2663">amiodarone</z:chebi> IV concentration </plain></SENT>
</text></document>